When Connecticut was facing a projected budget gap of $3.8 billion, the governor's office and a coalition of unions considered how to make changes to the state health plan in order to mitigate the shortfall.
This article was collaboratively written by A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design (V-BID), and several V-BID Center staff.
In fiscal year 2012, the State of Connecticut faced a projected budget gap of $3.8 billion. The governor’s office and a coalition of unions representing state employees considered a wide range of options to mitigate this shortfall, including changes to the state health plan covering active and retired state employees. The parties focused healthcare discussions on methods to improve health as a means to control long-term costs. This led to the October 2011 launch of an uncommonly innovative initiative—the Connecticut Health Enhancement Program (HEP).
HEP is designed to incorporate the principles of value-based insurance design (VBID). This entails: 1) reducing financial barriers that deter use of evidence-based services and high-performing providers; and 2) imposing disincentives that discourage use of low-value care. By eliminating barriers to specified clinical services based on beneficiary demographics and medical history, payers, purchasers, taxpayers, and consumers can attain more health for every dollar spent.
To learn more about the Connecticut Health Enhancement Plan, view the infographic below, and read the issue brief and 2015 update on the V-BID Center website.
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More